相关实验视频

Updated: Sep 17, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

IL1A:一种新的预后生物标志物和脏清细胞癌的潜在治疗标

J I Zeng^1,2,3, Xueteng Meng^1,3, Yuan Zhang^1,3

¹Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, 230032, China.

Oncology research

|July 4, 2025

概括

这项研究表明,在细胞癌 (RCC) 中,某些介质蛋白 (ILs) 的上调,而另一些的下调,影响预后. 互白素1A (IL1A) 显示出作为RCC的抗瘤剂的潜力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

细胞癌 (RCC) 是一种严重的癌症,发病率和死亡率不断增加.
互白蛋白 (ILs) 在免疫调节中发挥作用,并具有抗瘤特性.
有限的研究存在于IL表达和预后价值在RCC.

研究的目的:

为了全面分析RCC中的IL表达水平.
为了确定在RCC患者中ILs的预后意义.
阐明与差异表达ILs相关的功能途径和免疫细胞相互作用.

主要方法:

使用了多种生物信息学工具 (Oncomine,UALCAN,GEPIA,卡普兰-梅尔绘图器,cBioPortal,GeneMANIA,TRUST,STRING,链接的奥米克).
在RCC组织中分析了各种互白蛋白的转录水平.
与病态阶段,预后和免疫细胞透相关的IL表达.

主要成果:

在RCC中,IL4,IL7,IL15,IL16,IL23A,IL26和IL32的上调;IL1A,IL11和IL27的下调.
IL表达与RCC病理阶段和患者预后相关.
差异表达的ILs参与了细胞因子-细胞因子受体相互作用和免疫信号通路.
IL1A可能通过中性粒细胞外细胞陷 (NET) 产生抗瘤作用.

结论:

这项研究突出了RCC中互白蛋白的差异表达.
IL1A在RCC中显示出潜在的预后价值和抗瘤作用.
这些发现为进一步对RCC中的IL进行体内和临床研究提供了基础.

关键词:

生物标志物生物标志物炎症炎症是一种炎症.介质蛋白是介质蛋白中的一种.预测预后预测预测细胞癌是细胞癌.瘤发生的起源

更多相关视频

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...